Ofatumumab in the treatment of non-Hodgkin's lymphomas

被引：10
|
作者：
Karlin, Lionel [1 ]
Coiffier, Bertrand [1 ]
机构：
[1] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Hematol, F-69495 Pierre Benite, France
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2015年 / 15卷 / 07期
关键词：
diffuse large B-cell lymphoma; follicular lymphoma; ofatumumab; B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; REFRACTORY FOLLICULAR LYMPHOMA; ANTI-CD20; MONOCLONAL-ANTIBODY; PHASE-II TRIAL; PLUS RITUXIMAB; TARGETING BTK; CHEMOTHERAPY; MULTICENTER; COMBINATION;
D O I：
10.1517/14712598.2015.1055241
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Introduction: Ofatumumab is a second-generation humanized monoclonal antibody targeting CD20 registered for the treatment of patients with relapsing/refractory chronic lymphocytic leukemia. This review will describe the activity of ofatumumab in patients with CD20 B-cell lymphomas. Areas covered: A review of all manuscript published on ofatumumab activity in B-cell lymphomas is presented with conclusions on the future use of this antibody in these patients. Expert opinion: Ofatumumab activity is low in indolent or aggressive B-cell lymphomas. The future of this drug is challenged by new monoclonal antibodies and new targeted drugs.
引用
收藏
页码：1085 / 1091
页数：7
相关论文
共 50 条
  • [1] Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia
    Bello, Celeste
    Veliz, Marays
    Pinilla-Ibarz, Javier
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (03) : 295 - 300
  • [2] Treatment of indolent non-Hodgkin's Lymphomas
    Moreno Nogueira, J. A.
    Casas Fernandez de Tejerina, A.
    Moreno Rey, C.
    REVISTA CLINICA ESPANOLA, 2009, 209 (02): : 82 - 87
  • [3] Treatment of non-Hodgkin's lymphomas in the elderly
    Späth-Schwalbe, E
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2001, 34 (04): : 263 - 268
  • [4] Treatment of aggressive non-Hodgkin's lymphomas
    Kaiser, U
    Trumper, L
    Pfreundschuh, M
    Havemann, K
    INTERNIST, 1997, 38 (02): : 135 - 142
  • [5] Bendamustine in the treatment of non-Hodgkin's lymphomas
    Hagemeister, Fredrick
    Manoukian, George
    ONCOTARGETS AND THERAPY, 2009, 2 : 269 - 279
  • [6] Non-Hodgkin's lymphomas: Epidemiology and treatment
    Magrath, IT
    CHALLENGES AND OPPORTUNITIES IN PEDIATRIC ONCOLOGY, 1997, 824 : 91 - 106
  • [7] Treatment of aggressive non-Hodgkin's lymphomas
    Moreno Nogueira, J. A.
    Ruiz Borrego, M.
    Perez Valderrama, B.
    Valero Azbiru, M.
    REVISTA CLINICA ESPANOLA, 2009, 209 (02): : 88 - 92
  • [8] Hodgkin's and Non-Hodgkin's lymphomas
    Rademaker, Juergen
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2007, 45 (01) : 69 - +
  • [9] Non-hodgkin's lymphomas
    Bone Marrow Transplantation, 2000, 25 (Suppl 1) : S186 - S187
  • [10] Non-Hodgkin's Lymphomas
    Zelenetz, Andrew D.
    Abramson, Jeremy S.
    Advani, Ranjana H.
    Andreadis, C. Babis
    Byrd, John C.
    Czuczman, Myron S.
    Fayad, Luis
    Forero, Andres
    Glenn, Martha J.
    Gockerman, Jon P.
    Gordon, Leo I.
    Harris, Nancy Lee
    Hoppe, Richard T.
    Horwitz, Steven M.
    Kaminski, Mark S.
    Kim, Youn H.
    LaCasce, Ann S.
    Mughal, Tariq I.
    Nademanee, Auyporn
    Porcu, Pierluigi
    Press, Oliver
    Prosnitz, Leonard
    Reddy, Nashitha
    Smith, Mitchell R.
    Sokol, Lubomir
    Swinnen, Lode
    Vose, Julie M.
    Wierda, William G.
    Yahalom, Joachim
    Yunus, Furhan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (03): : 288 - 334
12345